Phase 2 N=21 Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures
Heart Failure
Primary: Characterize the Technical Feasibility of the Network Based IPC System — 72 percentage of days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=254 Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
Asthma
Primary: Asthma Exacerbations — 0.37; 0.48 exacerbations per year
Phase 2 N=82 Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg
N/A N=20 A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia
Major Depression · Fibromyalgia
Primary: Average Pain — 5.60; 5.43; 4.90; 5.49 units on a scale
Phase 1 N=3 T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs
Type 1 Diabetes Mellitus
Primary: Adverse Events (AEs) as a Measure of Safety and Tolerability — 25; 19; 31; 29 adverse events
N/A N=984 MyNewOptions: An Online Study of Reproductive Life Planning and Contraceptive Action Planning
Contraceptive Use · Unintended Pregnancy
Primary: Contraceptive Use — 93.43; 94.46; 94.10 percentage of surveys — p=1.0
N/A N=18 Use of Ultrasound Guidance to Assist With Labor Epidural Placement in Patients With a BMI ≥40
Labor Pain
Primary: Total Time Required for Epidural Catheter Placement — 6.1; 11.0 Minutes
Phase 2 N=17 Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence
Cocaine Dependence
Primary: Number of Participants Maintained on the Maximum Lisdexamfetamine Daily Dose. — 12 Participants
N/A N=170 The Advocate Study
Ostomy
Primary: Stoma Related Cost of Care — 223.73; 260.19 USD
N/A N=87 Physical Activity and Neuropsychological Outcomes in a Cancer Population
Cognitive Dysfunction · Breast Cancer Survivors
Primary: National Institutes of Health Toolbox - Cognition Domain- Oral Symbol Digit Test — 7; 3 units on a scale — p=<0.05
Phase 3 N=613 Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2
Skin Structures and Soft Tissue Infections
Primary: Percent of Participants With ≥20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline — 78.3; 76.7 percentage of participants
Phase 2 N=27 Danazol for Genetic Bone Marrow and Lung Disorders
Aplastic Anemia
Primary: Number of Patients Having Attenuation of Accelerated Telomere Attrition — 12 Participants
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
N/A N=262 Evaluation of Astigmatic Contact Lenses
Visual Acuity
Primary: Monocular Distance Visual Acuity (VA) — 258; 263 Eyes
Phase 4 N=305 Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
Schizophrenia · Schizoaffective Disorder
Primary: Substantial Clinical Deterioration Measured by Psychotic Symptoms — 1.8; 2.0 units on a scale